Efficacy of combination of topical 5% dapsone plus oral doxycycline versus topical adapalene plus oral doxycycline in the treatment of moderate acne vulgaris
DOI:
https://doi.org/10.66344/jpad.v36i1.3290Keywords:
Acne Vulgaris Dapsone DoxycyclineAbstract
Background Acne vulgaris is one of the most prevalent dermatological conditions worldwide, particularly affecting adolescents and young adults, with significant psychological and social impact. Topical and systemic agents are commonly combined to target multiple pathogenic pathways, yet comparative data on optimal regimens remain limited in the Pakistani population Objective To compare the efficacy of combination of topical 5% dapsone and oral Doxycycline versus topical adapalene and oral Doxycycline in the treatment of moderate acne vulgaris. Methods This Quasi Experimental Study with two arms was conducted at the Department of Dermatology, MTI-Hayatabad Medical Complex (HMC), Peshawar, from 01 October 2023 to 01 April 2024. A total of 160 patients were enrolled, with 80 patients in each group. Group A received topical 5% dapsone and oral Doxycycline, while Group B received topical adapalene and oral Doxycycline. Efficacy was evaluated using the Global Acne Grading System (GAGS) after 12 weeks of treatment. Results In Group A, 27.5% showed excellent efficacy, while 26.25% in Group B showed similar results. Good and fair efficacy was observed in 25% of both groups. No significant difference in overall efficacy was observed between the groups (p=0.780). Conclusion Both treatment combinations are effective for moderate acne vulgaris, with no statistically significant difference in efficacy between the groups. Either treatment regimen can be considered for managing moderate acne.References
Rathi SK. Acne vulgaris treatment: the current scenario. Indian J Dermatol. 2011;56(1):7-13.
Leung AKC, Barankin B, Lam JM, Leong KF, Hon KL. Dermatology: How to manage acne vulgaris. Drugs Context. 2021;10:2021-8-6.
Ayer J, Burrows N. Acne: more than skin deep. Postgrad Med J. 2006;82(970):500-6.
Mudassir M, Amar A, Raza N, Khokhar A, Siddiqui A, Ahmed N. Comparison of monthly pulse of oral azithromycin with daily Doxycycline in the treatment of moderate acne vulgaris. Pak Armed Forces Med J. 2022;71(S1):S268-72
Tan AU, Schlosser BJ, Paller AS. A review of diagnosis and treatment of acne in adult female patients. Int J Women's Dermatol. 2018;4(2):56-71.
Baldwin H. Oral antibiotic treatment options for acne vulgaris. J Clin Aesthet Dermatol. 2020;13(9):26-32.
Tolaymat L, Dearborn R, Zito PM. Adapalene. In: Stat Pearls. Treasure Island (FL): StatPearls Publishing; 2022.
Wang X, Wang Z, Sun L, Liu H, Zhang F. Efficacy and safety of Dapsone gel for acne: a systematic review and meta-analysis. Ann Palliat Med. 2022;11(2):611-20.
Nicklas C, Rubio R, Cárdenas C, Hasson A. Comparison of efficacy of aminolaevulinic acid photodynamic therapy vs. Adapalene gel plus oral Doxycycline for treatment of moderate acne vulgaris-A simple, blind, randomized, and controlled trial. Photodermatol. 2019;35(1):3-10.
Darjani A, Aboutaleb E, Alizadeh X, Rafiei R, Gharaee Nejad K, Nabatchii S, Rafiei E, Atrkar Roushan Z, Eftekhar H. Efficacy, safety, and tolerability of Dapsone 5% gel and benzoyl peroxide 5% gel in combination with oral Doxycycline in treating moderate acne vulgaris: a randomized clinical trial. Iranian J Dermatol. 2022 Jun 1;25(2):132-41.
Zaenglein AL. Topical retinoids for maintenance therapy of acne vulgaris. J Am Acad Dermatol. 2015;72(3):539-44.
Dhaher SR Luaibi M. Efficacy and Safety of Combined Isotretinoin and Azithromycin for Treatment of Severe Nodulocystic Acne. The Med J Basrah Univ. 2016;34(2):68-76.
Singh P, Barbieri JS, James WD, Thiboutot D. Letter to the Editor From Singh et al: "Female Adult Acne and Androgen Excess: A Report from the Multidisciplinary Androgen Excess and PCOS Committee". J Endocr Soc. 2022 Oct 14;6(12):bvac156. doi: 10.1210/jendso/bvac156.
Zaenglein AL, Graber EM, Thiboutot DM, Webster GF. Topical retinoids in the treatment of acne: status and future developments. Exp Opin Pharmacother. 2012;13(15):2131-45.
Kircik LH. Use of Dapsone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Dapsone 5% Gel Combination Treatment. J Drugs Dermatol. 2016 Feb 1;15(2):191-5.
Bhate K, Williams HC. What's new in acne? An analysis of systematic reviews published in 2017 and 2018. Clin Exp Dermatol. 2019;44(3):249-58.
Eichenfield LF, Krakowski AC, Piggott C, Del Rosso J, Baldwin H, Friedlander SF. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013;131(Suppl 3):S163-86.
Zaenglein AL. Acne vulgaris. N Engl J Med. 2018;379(14):1343-52.
Zhu JT, Xuan M, Zhang YN, Liu HW, Cai JH, Wu YH, Xiang XF, Shan GQ, Cheng B. The efficacy of autologous platelet-rich plasma combined with erbium fractional laser therapy for facial acne scars or acne. Mol Med Rep. 2013 Jul;8(1):233-7.
Galal O, Tawfik AA, Abdalla N, Soliman M. Fractional CO₂ laser versus combined platelet-rich plasma and fractional CO₂ laser in treatment of acne scars: image analysis system evaluation. J Cosmet Dermatol. 2019;18(6):1665-71.
Wu N, Sun H, Sun Q, Cong L, Liu C, Zheng Y, et al. A meta-analysis of fractional CO₂ laser combined with PRP in the treatment of acne scars. Lasers Med Sci. 2021;36(1):1–12.
Rahman S, Naveed T, Afridi Wu N, Sun H, Sun Q, Cong L, Liu C, Zheng Y, Ma L, Cong X. A meta-analysis of fractional CO2 laser combined with PRP in the treatment of acne scar. Lasers Med Sci. 2021 Feb;36(1):1-12. doi: 10.1007/s10103-020-03105-z.
Rahman S, Naveed T, Afridi IU, Suhail MA, Khan DD, Khan M, Shiraz Z. Comparison of efficacy of micro-needling plus platelet-rich plasma and fractional CO2 laser plus platelet-rich plasma in the treatment of post-acne scars. J Pak Assoc Dermatol [Internet]. 2024 Dec.31 [cited 2026Mar.8];34(4 Suppl.):S83-S88.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Journal of Pakistan Association of Dermatologists

This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.